Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the Companies intend to use a U.S. Food and Drug Administration (FDA) rare pediatric disease priority review voucher in connection with the Biologics License Application (BLA) submission for alirocumab.  The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review.

Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., purchased the voucher from BioMarin GALNS Ltd., a direct, wholly-owned subsidiary of BioMarin Pharmaceutical, Inc., which had received it through the FDA's Rare Pediatric Disease Priority Review Voucher Program.  Sanofi and Regeneron will equally share the purchase price of $67.5 million.

"The priority review voucher program was established to provide incentives that would enhance innovation in key areas of unmet patient need," said Ned Braunstein, M.D., Vice President, Regulatory Affairs at Regeneron.  "Our decision to acquire and leverage the voucher is clear evidence that this program is a valuable incentive for biopharmaceutical companies."

Sanofi and Regeneron expect to submit U.S. and EU regulatory submissions for alirocumab before year end.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated for its potential to lower low-density lipoprotein cholesterol (LDL-C) in patients who are not at their current LDL-C target with standard lipid-modifying therapies.

The Pediatric PRV was created by the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) and is intended to encourage th
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Florida (PRWEB) April 23, 2015 ... it intends to conduct a groundbreaking pilot study ... to be reversed in as little as three ... science of metabolic and nutritional medicine—will aggressively target ... cripple and destroy our aging brain. These include ...
(Date:4/23/2015)... 2015 Six startups from Russia ... 4-17 as part of the U.S.-Russia Innovation Corridor ... of biotechnology startups to participate in the program ... and the University of Maryland (UMD) signed a ... respective universities in the biomedical industry in 2013. ...
(Date:4/23/2015)... 23, 2015 Follow us ... a series of genetic tests that determine individual ... Gehrig's disease, Huntington's disease, and Alzheimer's disease. Predictive ... composition and interaction in diseased tissue/cells to understand ... as the response to treatment, such as in ...
(Date:4/23/2015)... , April 23, 2015 ... Equipment   Report Details   We ... a value of $101.3 billion in 2015 and will grow ... growth in the healthcare sectors around the world and increasing ... key growth factors in the global healthcare packaging ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10
... in Second Half 2008, ANNAPOLIS, Md., Aug. ... biodefense company developing medical countermeasures,against biological and chemical ... second quarter and six months ended June 30,2008. ... -- Submitted response to a Request for ...
... More than 35% Compared to the previous Quarter ... Production Reaches 200,000 OmniPods per Month, BEDFORD, Mass., Aug. ... patch pump technology with its OmniPod(R),Insulin Management System, today announced ... 30, 2008., Second quarter 2008 reported revenue increased 131% ...
... Biosciences continues to,expand its offering of IRDye ... IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye 800CW,Donkey ... and IRDye 800CW Goat,Anti-Rat IgG antibodies are ... for multiple applications including,quantitative Westerns, In-Cell Westerns, ...
Cached Biology Technology:PharmAthene Reports Second Quarter 2008 Financial and Operational Results 2PharmAthene Reports Second Quarter 2008 Financial and Operational Results 3PharmAthene Reports Second Quarter 2008 Financial and Operational Results 4PharmAthene Reports Second Quarter 2008 Financial and Operational Results 5PharmAthene Reports Second Quarter 2008 Financial and Operational Results 6PharmAthene Reports Second Quarter 2008 Financial and Operational Results 7PharmAthene Reports Second Quarter 2008 Financial and Operational Results 8Insulet Reports Second Quarter 2008 Results 2Insulet Reports Second Quarter 2008 Results 3Insulet Reports Second Quarter 2008 Results 4Insulet Reports Second Quarter 2008 Results 5Insulet Reports Second Quarter 2008 Results 6Insulet Reports Second Quarter 2008 Results 7Insulet Reports Second Quarter 2008 Results 8
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... unique Mayo Clinic collaboration has revived the healing wisdom ... extract described in a 17th century Dutch herbal text ... from the Atun tree effectively control bacteria that can ... circa 1650. He documented his traditional healing methods in ...
... and Hispanic patients and those who are uninsured are less ... been associated with better outcomes, according to a study in ... improve the quality of surgical care in the United States ... hospitals for certain procedures, since a number of studies have ...
... experiments of their kind, researchers at Rice University and ... have determined that carbon nanotubes injected directly into the ... health effects and circulate for more than one hour ... findings are from the first in vivo animal study ...
Cached Biology News:Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug 2Minorities, uninsured less likely to receive care at high-volume hospitals 2Pure carbon nanotubes pass first in vivo test 2
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
GOAT ANTI PPP2R5B...
... Molecular Probes Fc OxyBURST Green reagent ... Simons of Boston University to permit measurement ... internalization and the subsequent oxidative burst directly ... assay reagent consists of bovine serum albumin ...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
Biology Products: